PTP1B-IN-9 (Synonyms: NSC 638643) |
| Catalog No.GC61221 |
PTP1B-IN-9는 유비퀴틴-프로테아좀 시스템(UPS) 스트레스 요인입니다. PTP1B-IN-9는 20S 프로테아솜 촉매 활성의 상류에서 유비퀴틴 매개 단백질 분해를 억제합니다. PTP1B-IN-9는 20S 프로테아좀 촉매 활성에 영향을 미치지 않으면서 유비퀴틴-프로테아좀-시스템(UPS) 스트레스 반응을 유발합니다. 항암 활성.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 145888-79-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PTP1B-IN-9 is a ubiquitin-proteasome system (UPS)-stressor. PTP1B-IN-9 inhibits ubiquitin-mediated protein degradation upstream of the 20S proteasomal catalytic activites. PTP1B-IN-9 triggers a ubiquitin-proteasome-system (UPS)-stress response without affecting 20S proteasome catalytic activities. Anticancer activity[1].
PTP1B-IN-9 (0-30 µM; 48 hours) treatment produces a dose dependent reduction in the viability of HPV16-positive SiHa and Caski cells and HPV-39-positive ME180 cervical cancer cell lines respectively[1].PTP1B-IN-9 reduces the cell viability of exponentially growing HeLa cervical cancer cells in a dose-dependent fashion with an IC50 value of 2 µM[1]. Cell Viability Assay[1] Cell Line: Keratinocytes, SiHa, CaSki and ME180 cells
[1]. Anchoori RK, et al. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells.PLoS One. 2011;6(8):e23888.
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *